PUNE: In a significant step towards building a drug-free future through youth participation and institutional collaboration, Pune Police will organise the No Drugs Volunteer campaign at Dr. P. A. Inamdar University, Azam Campus, on Tuesday, April 7, 2026, at 11:00 am.

The initiative, being held in association with Lashkar Police Station, Awami Mahaz and Padmapani Foundation, is designed to address the growing concern of drug abuse among young people through awareness, prevention and community engagement. More importantly, by hosting the programme at a university campus, the organisers are placing students at the heart of a wider social movement aimed at protecting Pune’s youth from the dangers of addiction.

The programme will be held under the chairmanship of Mrs. Abeda Inamdar, President, Maharashtra Cosmopolitan Education Society, Pune. Pune Police Commissioner Amitesh Kumar will directly interact with students during the session. Senior officials, including Joint Commissioner of Police Ranjankumar Sharma, Additional Commissioner of Police Manoj Patil, Deputy Commissioners of Police Rajlakshmi Shivankar and Nikhil Pingale, along with Rahul Dumbale of Padmapani Foundation, will also be present.

The No Drugs Volunteer campaign is intended to build a strong network of young volunteers who can become awareness ambassadors in their communities and educational spaces. The initiative aims to sensitise youth in the 15 to 30 age group about the physical, psychological, and social consequences of drug abuse, while encouraging informed dialogue around prevention, rehabilitation, and the role of society in early intervention.

Mrs. Abeda Inamdar, President, Maharashtra Cosmopolitan Education Society, Pune, said, “A university is not only a place of academic learning, but also a space where responsible citizenship is shaped. If we want to secure the future of our society, we must empower young minds with awareness, courage, and clarity. Through this initiative, we want students to understand that saying no to drugs is not just a personal choice, but a social responsibility.”

Pune Police Commissioner Amitesh Kumar said, “The fight against drugs cannot be won by enforcement alone. It requires trust, awareness and active participation from the community, especially the youth. Through the No Drugs Volunteer initiative, our vision is to create a people-supported movement in which students become partners in prevention and ambassadors of a healthier, safer and drug-free Pune.”

With the participation of senior police leadership, educational authorities, and community organisations, the programme is expected to send out a strong message that the battle against drugs must begin with awareness, vigilance, and collective resolve

The post Pune Police Commissioner Amitesh Kumar to Spearhead Anti-Drug Youth Dialogue at Dr. P. A. Inamdar University appeared first on NRI News.

MUMBAI: Building on its international presence in the oncology space, Venus Remedies, a global leader in pharmaceutical innovation, has secured marketing authorization for docetaxel from Israel and cytarabine from Colombia.

While docetaxel, an antineoplastic agent, is beneficial in the treatment of breast, prostate, head, neck, and non-small cell lung cancer, cytarabine is useful in acute non-lymphocytic leukemia, acute lymphocytic leukemia, and chronic myelocytic leukemia.

Israel’s pharmaceutical market, valued at about $5 billion, is projected to grow at a five-year compound annual growth rate (CAGR) of 4.2% up to 2026. Israel has a dynamic pharmaceutical expanse known for its innovation and commitment to healthcare excellence. The marketing
authorization for cytarabine from Colombia, on the other hand, marks a significant expansion of Venus Remedies in the Latin American market. Colombia, the third-largest pharmaceutical market in South America projected to grow at a five-year CAGR of 3.1% up to 2026, has emerged as a vital player in the pharmaceutical industry, exhibiting robust growth and fostering innovation. The Colombian market dominated by oncology drugs has witnessed steady expansion.

Saransh Chaudhary, CEO, of Venus Medicine Research Centre (VMRC), said “These dual milestones reflect VMRC’s unwavering dedication to research and development. “Our team’s relentless pursuit of excellence in pharmaceutical innovation is evident in the approvals for docetaxel and cytarabine. We are excited about the prospect of bringing these advanced therapies to patients in Israel and Colombia, and we remain committed to exploring new frontiers in healthcare that align with our vision of a healthier world”.

Hailing the achievement, Aditi K. Chaudhary, President, International Business, Venus Remedies, said, “These marketing approvals mark a significant stride in our global mission to enhance healthcare accessibility. One of the largest exporters of docetaxel, Venus Remedies is proud to include Israel in the list of countries it supplies docetaxel to, including Malaysia, Namibia, Myanmar, Panama, Indonesia, Iraq, Tanzania, Germany, and Zimbabwe. Likewise, the market reach of Venus Remedies for cytarabine extends to Guinea-Bissau, Jordan, Namibia, Oman, Saudi Arabia, Tunisia, and Venezuela, besides Colombia.“

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America, and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi, and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001, and OHSAS. The company has also been approved by European-GMP, WHO-GMP, and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and has more than 125 registered trademarks and 25 copyrights for its innovative research products.

The post Venus Remedies Secures Marketing Approval from Israel and Colombia for Two Oncology Drugs appeared first on NRI News.

Clinical trials play a pivotal role in the development and evaluation of new research drugs for life-threatening conditions such as Cancer, Cardiac disease, liver disease, and numerous other ailments. These trials involve a meticulous process encompassing drug discovery, synthesis, screening for optimal efficacy, and stringent safety assessments. The journey from the initial stages of drug development to its availability in the market spans several years, typically ranging from 12 to 15 years. This comprehensive and time-consuming process is indispensable for ensuring the safety and efficacy of potential treatments.

Keeping this in mind, Sahyadri Hospitals has established an exceptional clinical research department, supported by a robust ethics committee. This dynamic team has been instrumental in conducting all phases of drug trials with unwavering dedication, systematicity, and efficiency. Over the past 13 years, Sahyadri Hospitals has successfully conducted more than 300 clinical trials, benefiting thousands of patients and contributing significantly to the advancement of medical knowledge.

“At Sahyadri Hospitals, we are dedicated to driving innovative research and transforming healthcare through our comprehensive clinical trials,” stated Dr. Deepa Divekar, Research Director, Sahyadri Hospitals Pvt Ltd. “By upholding the highest ethical standards and ensuring patient safety, we have become a preferred site for national and international pharmaceutical companies to conduct crucial trials on human subjects“

Clinical trials conducted at Sahyadri Hospitals have opened new avenues for medical advancements, offering hope to patients battling challenging health conditions. Through these trials, innovative research drugs have shown remarkable promise in transforming patient lives, delivering improved treatment outcomes, and paving the way for novel therapeutic approaches.

As Sahyadri Hospitals continues to drive healthcare innovation through its groundbreaking clinical trials, it remains committed to advancing patient care, striving for excellence, and shaping the future of medicine.

The post Sahyadri Hospitals Leads the Way in Clinical Trials for Revolutionary Research Drugs appeared first on NRI News.